Adell Harriman & Carpenter Inc. Sells 1,500 Shares of Agilent Technologies, Inc. (NYSE:A)

Adell Harriman & Carpenter Inc. trimmed its position in shares of Agilent Technologies, Inc. (NYSE:A) by 39.0% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 2,344 shares of the medical research company’s stock after selling 1,500 shares during the period. Adell Harriman & Carpenter Inc.’s holdings in Agilent Technologies were worth $326,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Massachusetts Financial Services Co. MA raised its stake in Agilent Technologies by 0.4% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 11,076,270 shares of the medical research company’s stock worth $1,238,549,000 after buying an additional 39,030 shares during the period. Wellington Management Group LLP grew its position in Agilent Technologies by 17.4% in the 3rd quarter. Wellington Management Group LLP now owns 10,255,526 shares of the medical research company’s stock valued at $1,146,773,000 after purchasing an additional 1,519,134 shares during the period. Northern Trust Corp raised its holdings in Agilent Technologies by 6.6% during the third quarter. Northern Trust Corp now owns 4,097,313 shares of the medical research company’s stock worth $458,162,000 after buying an additional 254,998 shares during the last quarter. Bank of New York Mellon Corp grew its holdings in shares of Agilent Technologies by 4.9% during the third quarter. Bank of New York Mellon Corp now owns 2,677,277 shares of the medical research company’s stock valued at $299,373,000 after buying an additional 124,671 shares during the last quarter. Finally, Nordea Investment Management AB increased its position in shares of Agilent Technologies by 233.7% during the fourth quarter. Nordea Investment Management AB now owns 2,666,416 shares of the medical research company’s stock worth $370,552,000 after acquiring an additional 1,867,377 shares in the last quarter.

Insider Activity at Agilent Technologies

In related news, CEO Michael R. Mcmullen sold 52,297 shares of the stock in a transaction dated Friday, March 8th. The shares were sold at an average price of $150.00, for a total value of $7,844,550.00. Following the sale, the chief executive officer now directly owns 253,909 shares of the company’s stock, valued at approximately $38,086,350. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, CEO Michael R. Mcmullen sold 52,297 shares of the stock in a transaction dated Friday, March 8th. The shares were sold at an average price of $150.00, for a total transaction of $7,844,550.00. Following the sale, the chief executive officer now owns 253,909 shares of the company’s stock, valued at $38,086,350. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Rodney Gonsalves sold 4,828 shares of the stock in a transaction on Thursday, March 7th. The shares were sold at an average price of $149.00, for a total transaction of $719,372.00. Following the completion of the transaction, the vice president now directly owns 21,329 shares in the company, valued at $3,178,021. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 61,610 shares of company stock valued at $9,220,333.

Agilent Technologies Stock Performance

A traded down $0.44 during midday trading on Tuesday, hitting $139.15. 82,670 shares of the company traded hands, compared to its average volume of 1,534,898. The company’s 50-day moving average is $141.69 and its 200 day moving average is $131.02. Agilent Technologies, Inc. has a 52 week low of $96.80 and a 52 week high of $151.58. The firm has a market capitalization of $40.78 billion, a PE ratio of 33.24, a price-to-earnings-growth ratio of 4.17 and a beta of 1.11. The company has a quick ratio of 2.04, a current ratio of 2.68 and a debt-to-equity ratio of 0.41.

Agilent Technologies (NYSE:A) last announced its quarterly earnings data on Tuesday, February 27th. The medical research company reported $1.29 EPS for the quarter, beating the consensus estimate of $1.22 by $0.07. Agilent Technologies had a return on equity of 27.09% and a net margin of 18.35%. The business had revenue of $1.66 billion for the quarter, compared to the consensus estimate of $1.59 billion. During the same period in the previous year, the business earned $1.37 earnings per share. The business’s revenue was down 5.5% on a year-over-year basis. On average, research analysts expect that Agilent Technologies, Inc. will post 5.5 EPS for the current year.

Agilent Technologies Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Wednesday, April 24th. Shareholders of record on Tuesday, April 2nd were issued a dividend of $0.236 per share. This represents a $0.94 annualized dividend and a yield of 0.68%. The ex-dividend date of this dividend was Monday, April 1st. Agilent Technologies’s dividend payout ratio is presently 22.38%.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on A. Oppenheimer boosted their target price on Agilent Technologies from $67.00 to $90.00 and gave the stock an “outperform” rating in a research note on Tuesday, March 26th. Evercore ISI increased their target price on shares of Agilent Technologies from $132.00 to $145.00 and gave the stock an “in-line” rating in a research report on Thursday, April 4th. Barclays lifted their target price on shares of Agilent Technologies from $125.00 to $135.00 and gave the stock an “underweight” rating in a research note on Wednesday, April 10th. Stifel Nicolaus raised shares of Agilent Technologies from a “hold” rating to a “buy” rating and raised their price objective for the stock from $145.00 to $163.00 in a report on Friday, April 5th. Finally, Citigroup lifted their price target on Agilent Technologies from $130.00 to $145.00 and gave the company a “neutral” rating in a research report on Wednesday, February 28th. One research analyst has rated the stock with a sell rating, five have given a hold rating and twelve have issued a buy rating to the company. According to data from MarketBeat.com, Agilent Technologies has a consensus rating of “Moderate Buy” and a consensus price target of $141.29.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.